Norethindrone acetate/ethinyl estradiol tablets approved July 2 for treatment of moderate acne vulgaris in women at least 15 years of age. The supplemental application for the oral contraceptive was submitted April 2000
You may also be interested in...
Schering AG's Berlex subsidiary will highlight Yasmin 20's lower estrogen dose and 24-day hormone treatment regimen in marketing the oral contraceptive
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011